Combined mass spectrometry-guided genome mining and virtual screening for acaricidal activity in secondary metabolites of \textit{Bacillus velezensis} W1†

Xingyu Li‡a,b, Shahzad Munir, Li‡c, Yan Xub, Yuehu Wanga and Yueqiu Heªc

A comprehensive analytic strategy was performed to study the acaricidal activity ingredients of \textit{Bacillus velezensis} W1, a strain for biological control of \textit{Tetranychus urticae}. Through genome mining, 14 biosynthetic gene clusters were identified, which encode secondary metabolites, and these were further confirmed by MALDI-TOF-MS or LC-ESI-MS/MS, including bacillomycin D C13–C17, macrolactin A, 7-O-malonyl-macrolactin A, surfactin C14, and surfactin C15. Moreover, 27 volatile compounds were identified by GC-MS, mainly including cyclodipeptides, alkanes, organic acids, and esters. Finally, 43 compounds identified from W1 were used in the virtual screening of acaricidal activity. The results showed that 16 compounds, including cyclodipeptides, bacillomycins, macrolactins, and surfactins, have acaricidal potential. This work provides a base for studying the mechanism of acaricidal action of \textit{B. velezensis} W1 and a comprehensive strategy for the study of active ingredients from biocontrol strains.

Introduction

\textit{Bacillus velezensis} is a Gram-positive and endospore-forming bacterium that is enriched in various environments, including soil, plants, marine habitats, and intestinal microflora. A variety of strains have been used as an ecologically safe biological pesticide and plant growth promoter, such as \textit{B. velezensis} FZB42, which has been developed as a natural commercial agent Rhizivoital® to control a variety of soil-borne diseases, and \textit{B. velezensis} strain has been commercialized in the form of fungicide Botrybel. The secondary metabolites produced by \textit{B. velezensis} play a vital role in biocontrol activities, such as cyclic lipopeptides (i.e., surfactin, bacillomycin, fengycin, iturin, and bacillibactin), polyketides (i.e., macrolactin, bacilaene, and difficidin), and various low molecular weight metabolites), some of which can directly or indirectly control plant pathogens, promote plant growth, and induced systemic acquired resistance in plants.

Studies on the secondary metabolism of \textit{Bacillus} are usually started with screening crude extract for biological activity and then isolate, purify, identify, and characterize the active ingredients. This process has been proved to be effective and can promote the acquisition of active natural products. However, today, this is considered infeasible, mainly due to the high rate of rediscovery and frequent lack of trace components. With the development of modern chromatography technology and high-throughput genome sequencing technology, people have more options for the research methods of secondary metabolites of \textit{Bacillus}, e.g., the antibiotics and secondary metabolite analysis shell (antiSMASH) can quickly identify wide genome, annotate and analyze secondary metabolite biosynthetic gene clusters, and helps to estimate the types of compounds encoded by the gene clusters. Combining mass spectrometry and genome mining is an advantageous strategy for targeting new molecule backbones or harvesting metabolic profiles to identify analogs from known compounds. The prediction of activity spectra for substances (PASS) and Binding DB helps to estimate the compound’s possible biological activity based on its structural formulae.

\textit{Bacillus velezensis} W1, former name \textit{B. amyloliquefaciens} W1, later referred to as W1, can biologically control the phytophagous mite \textit{Tetranychus urticae}. Our previous studies found that W1 gene occupies about 116 kb, equivalent to 2.63% of its total genetic capacity, to be responsible for biosynthesis, transport, and catabolism of secondary metabolites, and eight cyclodipeptides with acaricidal activities have been identified through the bioassay-guided fractionation of W1 cell-free supernatant. There is scarce information about the acaricidal activity of the secondary metabolites of the biocontrol strains. Therefore, to completely understand the secondary metabolites of W1 and its acaricidal activity, genome mining, MS-based...
untargeted metabolite analysis, and virtual screening for acaricidal activity were used in the current work.

**Experimental and instrumentation**

**Bacillus velezensis W1**

The storage conditions, culture, and fermentation procedures of biocontrol strain W1 are the same as those of the previously published articles from our group, and our group has got the whole-genome sequences of W1 that was deposited in GenBank with an accession number CP028375.

**Genome mining of secondary metabolite gene clusters**

The whole-genome sequence of W1 was undergone antibiotic and secondary metabolite analysis shell (antiSMASH, version 5.1.2), used to check the biosynthetic gene clusters (BGCs), and further aligned using National Center for Biotechnology Information (NCBI) database though BLASTtool (https://www.ncbi.nlm.nih.gov/) against different databases. The antiSMASH web service for bacterial version is available from https://antismash.secondarymetabolites.org/ (accessed on April 6, 2020), which can compare the identified BGCs in genomes submitted by the user with a large number of other microbial BGCs or compiled the Minimum Information for Biosynthetic Gene Clusters (MIBiG) database (https://mibig.secondarymetabolites.org/, accessed on April 6, 2020), and then pointed out whether similar pathways exist in other organisms.

**Mass spectrometry-based untargeted metabolite analysis**

**MALDI-TOF MS analysis.** The secondary metabolites in whole-cell were characterized by MALDI-TOF-MS, which was performed on a Bruker UltraflexXTreme mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with a 337 nm nitrogen laser for desorption and ionization with reagent voltage set at 20 and 23.5 kV, respectively. MALDI-TOF-MS instrument. The spectrum was obtained by positive ion detection and reflector mode by accumulating 1000 laser shots in the m/z range 500–2000, and setting the acceleration and reflector voltage set at 20 and 23.5 kV, respectively.

**GC-MS analysis.** The 2.5 × 10^5 CFU inoculum of W1 was placed in 2000 mL LB broth and kept at 35 °C with pH 8 at 170 rpm in a shaking incubator for 72 h. Cell-free supernatant was prepared by centrifugation for 15 min at 12,000 rpm at ambient temperature. The supernatant was absorbed through D101-type macroporous adsorption resin column chromatography with 95% EtOH as the eluent, and then EtOH was removed with a vacuum rotary evaporator at 55 °C to obtain a crude extract (5 g). Three 0.3 mg crude extracts were extracted with petroleum ether, ethyl acetate, and acetone, respectively, were then analyzed by GC-MS, which was performed by GC-MS spectrometry (Hp6890GC/5973MS, Agilent Technologies, USA) with an HP-5MS fused-silica capillary column (30 m long, 0.25 mm id, 0.25 μm film thickness; Agilent Technologies, USA).

For GC-MS detection, the electron ionization system was conducted with ionization energy of 70 eV in ionization mode. Helium gas (99.999%) was used as the carrier gas at a constant flow rate of 1.0 mL min⁻¹, and an injection volume of 1.0 μL (a split ratio of 10 : 1) was operated. Temperature of the injector was kept at 250 °C, the temperature of the ion source was maintained at 230 °C, and the column pressure was 100 kPa. The oven temperature was 40 °C for 2 min, then gradually went up to 80 °C at a rate of 3 °C min⁻¹, then increased to 280 °C at a rate of 5 °C min⁻¹, and maintained at 280 °C for 30 min. Mass spectrum was collected at 70 eV, the scan interval was 0.5 s, and the size of a fragment was 35–500 Da. The solvent delay was 0–2 min, and the total GC-MS run time was 36 min. By comparing the average peak area of each element with the total area, the relative percentage of each component was calculated. A quadrupole mass spectrometer was used to obtain mass spectrometry data that were further matched with the Wiley 7n1 compound library.

**GC-MS analysis.** The crude extract was dissolved in MeOH with auxiliary ultrasound, then filtered through a 0.22 μM syringe-driven filter (Nylon 66). The MeOH solution was analyzed by LC-MS using a UFLC-MS-IT-TOF apparatus (Shimadzu, Kyoto, Japan) equipped with a diode array detector (DAD) and electrospray ionization (ESI) coupled with ion trap (IT) and time of flight (TOF) mass analyzers. Chromatographic separation was carried out using a Zorbax column (SB-Aq, 4.6 × 250 mm, 5 μm, Agilent Technologies) with a flow rate of 1 mL min⁻¹. A mobile phase consisting of 0.1% (v/v) formic acid (A) and acetonitrile (B) in water was used. Following linear gradient elution was used: 5% B at 0 min, increased to 100% B at 0 to 63 min, maintained at 100% B at 63 to 64 min, then decreased to 5% B at 64 to 65 min, and kept at 5% B until 66 min. The DAD profiles were recorded from 190 to 400 nm and monitored at 254 nm. The mass spectrometer was operated in the positive total ion full scan mode with mass scan range m/z 100–1500 using ESI under the following conditions: nebulizing gas (N₂) flow rate 1.5 L min⁻¹, drying gas pressure 100 kPa, interface (probe) voltage (+) 4.5 kV, interface (probe) voltage (−) 3.5 kV, curved desolvation line temperature 200 °C, heat block temperature 200 °C, detector voltage 1.58 kV, RP vacuum 63.1 Pa, IT area vacuum 1.2 × 10⁻² Pa, TOF area vacuum 1.1 × 10⁻⁴ Pa, and instrument temperature 40 °C. The molecular ion mass collected from LC-MS analysis was further analyzed by LC-MS/MS that was performed in an automatic pattern.

**Virtual screening for acaricidal active secondary metabolites**

By comparing the structural similarities between known acaricides and compounds identified from biocontrol strain W1, based on compounds with similar structures having similar biological activities, BindingDB Web service (http://
www.bindingdb.org/, accessed on April 6, 2020) was used to screen virtual acaricidal activity of W1 secondary metabolites. In detail, 32 known acaricidal compounds (Table S1†) were extracted from the DrugBank database (https://www.drugbank.ca/, accessed on April 6, 2020) by searching for the keywords “acaricidal” or “acaricide”. The SDfile of acaricidal pesticide as an active group was uploaded to BindingDB web service, and upload the SDfile of compounds identified from W1 as a set of query group. Finally, virtual screening results were obtained by selecting maximum similarity as a suitable screening model for using chemical fingerprints to quickly find similar compounds.7

Results and discussion

Genome mining of Bacillus velezensis W1 BGCs and corresponding secondary metabolites compound classes

Through genome mining, a total of 15 regions composing of the secondary metabolite BGCs and boundary genes were found in the W1 genome, 9 of which matched the 14 BGCs of known secondary metabolites. It is shown in Table 1, these regions accumulate BGCs that encode the known secondary metabolite enzymes, of which 3 BGCs (including srf, dhb, and bac) belong to non-ribosomal peptide synthetases (NRPSs) for surfactin, bacillibactin, and bacilysin, 4 BGCs (including btr, mln, fen, and pps) are polyketide synthase genes (PKS) for butirosin, macrolactin, fengycin, and plipastatin, 5 BGCs (including bae, bmy, myc, itu, and dif) are PKS–NRPS hydride synthetases for bacillaene, bacillomycin D, mycosubtilin, iturin, and difficidin, 2 BGCs (including can and lan) belong to head-to-tail cyclized peptide (RiPP) synthase genes for amycyclocyclin and mersacidin. Notably, in addition to compounds surfactin, butirosin, and iturin, the BGCs similarities of 11 other compounds matched 100% of known strains showed in Table 1. The potential strain Bacillus velezensis W1 was used previously with significant acaricidal activity against phytophagous mite Tetanychus urticae.9 Whole genome sequence of W1 strain was analyzed through antiSMASH to investigate the BGCs. A total of 15 regions comprising secondary metabolites BGCs were revealed. B. amyloliquefaciens FZB42 also encoded a hybrid type I PKS–NRPS gene cluster called bae.11 Notably, 5 BGCs including bae was also found in W1 strain that encode for PKS–NRPS hydride synthetases for bacillaene. Integrated approach of genome mining was used for B. velezensis LM2303 strain 13 BGCs encoding secondary metabolites having potential

![Fig. 1 MALDI-TOF MS spectrum of bacillomycin D from Bacillus velezensis W1.](image)

Table 1 | Comparison of secondary metabolite biosynthetic gene clusters in the Bacillus strains

| Region | Synthetase style | BGCs | Metabolite | MIBiGa | Similarity | Strains |
|--------|------------------|------|------------|--------|------------|---------|
| Region 1 | Lassopeptide | — | — | — | — | |
| Region 2 | NRPS | srf | Surfactin | BGC0000433 | 82% | FZB42b |
| Region 3 | Phosphonate | — | — | — | — | |
| Region 4 | PKS | btr | Butirosin | BGC0000693 | 7% | SANKc |
| Region 5 | Terpene | — | — | — | — | |
| Region 6 | PKS | mln | Macrolactin | BGC000181 | 100% | FZB42b |
| Region 7 | PKS–NRPS | bae | Bacillaene | BGC0001089 | 100% | FZB42b |
| Region 8 | PKS | fen | Fungycin | BGC0001095 | 100% | FZB42b |
| Region 9 | Terpene | — | — | — | — | |
| Region 10 | PKS | — | — | — | — | |
| Region 11 | PKS–NRPS | dif | Difficidin | BGC000176 | 100% | FZB42b |
| Region 12 | NRPS | dhb | Bacillibactin | BGC000309 | 100% | 168d |
| Region 13 | NRPS | can | Amylocyclin | BGC000616 | 100% | FZB42b |
| Region 14 | RiPP | bac | Bacilysin | BGC001184 | 100% | FZB42b |
| Region 15 | RiPP | lan | Mersacidin | BGC000527 | 100% | HIL-Y85e |

a Biosynthetic gene cluster-ID in the MIBiG database. b B. velezensis FZB42. c B. circulans SANK 72073. d B. subtilis XF-1, B. subtilis ATCC6633, B. subtilis RB14, B. subtilis 168. e B. sp. HIL-Y85/54 728. — indicates unknown information.
biocontrol functions. In another study, 19 candidate genes were recorded using this technology in *B. siamensis* SCSIO 05746.

**MALDI-TOF MS analysis**

By analyzing the mass spectrometry data detected by MALDI-TOF-MS and comparing it with the mass data of known *Bacillus* metabolites, four cyclic lipopeptide compounds of ituin family were identified from the whole cells of W1, which are homologues of bacillomycin D, consisting of a heptapeptide molecule linked to a β-amino fatty acid chain of 13–17 carbons atoms. The eight well-resolved clusters of peaks were detected, as shown in Fig. 1, and the precursor ions were assigned as proton, sodium, or potassium ion adducts of the four molecules. For example, the precursor ions at *m/z* 1031.65 ([M + H]⁺), and 1053.93 ([M + Na]⁺) were assigned as the protonated molecule and sodiated molecule of bacillomycin D C14 respectively, as shown in Table 2.

**GC-MS analysis**

GC-MS was used to detect the petroleum ether, ethyl acetate, and acetone extraction from the crude extract of W1, generating 41, 64, and 39 peaks, respectively (Fig. S1–S3†). Among them, 27 compounds were identified (Table 3) with a quality match of 63% minimum, including 6 cyclic dipeptides, 10 alkanes, 5 esters, 3 acids, 2 ketones, and one alcohol. Fig. 2 showed the matching quality of 6 cyclic dipeptides and their standard GC-MS spectra. For the spectra of other compounds, please refer to the attachment (Fig. S1–S3†). Our previous studies have identified 8 cyclic dipeptides using NMR and MS from the supernatant of W1 by column chromatography and HPLC. In this study, 6 cyclic dipeptides were identified by GC-MS as cyclo (Gly–Pro), cyclo (Leu–Leu), cyclo (Phe–Leu), cyclo (Phe–Pro), cyclo (Pro–Pro), and cyclo (Ala–Val), of which cyclo (Gly–Pro), and cyclo (Pro–Pro) are consistent with previous reports, while the rest are first discovered in strain W1.

### Table 2 Assignments of eight mass peaks obtained by MALDI-TOF MS of the whole cell of *Bacillus velezensis* W1

| Mass peaks (m/z) | Assignment | Ref. |
|-----------------|------------|------|
| 1017.594        | C13 bacillomycin D [M + H]⁺ | (Thasana, et al., 2010) |
| 1039.665        | C13 bacillomycin D [M + Na]⁺ | |
| 1031.647        | C14 bacillomycin D [M + H]⁺ | (Jin, et al., 2020) |
| 1053.933        | C14 bacillomycin D [M + Na]⁺ | (Ben Ayed, et al., 2017) |
| 1045.768        | C15 bacillomycin D [M + H]⁺ | |
| 1067.974        | C15 bacillomycin D [M + Na]⁺ | |
| 1082.005        | C16 bacillomycin D [M + Na]⁺ | |
| 1097.994        | C16 bacillomycin D [M + K]⁺ | |

### Table 3 Chemical composition of petroleum ether, ethyl acetate, and acetone extract from cell-free supernatant of *Bacillus velezensis* W1 using GC/MS analysis

| No. | Compound name | Exact mass | Formula | Qa (%) | Extractionb |
|-----|---------------|------------|---------|--------|-------------|
| 1   | Benzenecacetic acid | 136.05 | C₈H₈O₂ | 91 | PE, AT |
| 2   | Benzenebutanoic acid | 164.08 | C₁₀H₁₂O₂ | 86 | PE |
| 3   | Benzenepropanoic acid | 150.07 | C₁₀H₁₄O₂ | 96 | PE, EA, AT |
| 4   | 3-(O-Azidophenyl)propanol | 177.09 | C₈H₈N₂O₂ | 78 | EA |
| 5   | Docosane | 310.36 | C₂₂H₄₆ | 93 | PE, AT |
| 6   | Eicosane, 7-hexyl- | 366.42 | C₂₀H₃₄N₂O₂ | 90 | AT |
| 7   | Heptacosane | 301.44 | C₂₇H₅₄ | 97 | PE, AT |
| 8   | Heptacosane | 301.44 | C₂₇H₅₄ | 90 | AT |
| 9   | Hexadecane, 2,6,10,14-tetramethyl- | 282.33 | C₁₄H₂₂N₂O₂ | 86 | AT |
| 10  | Eicosane | 282.33 | C₁₄H₂₂N₂O₂ | 96 | AT |
| 11  | Nonadecane | 268.31 | C₁₉H₃₈ | 97 | PE, AT |
| 12  | Octadecane | 254.30 | C₁₈H₃₈ | 96 | AT |
| 13  | Pentacosane | 352.41 | C₂₅H₅₀ | 97 | AT |
| 14  | Tricosane | 324.38 | C₂₃H₄₆ | 93 | AT |
| 15  | Cyclo (Gly–Pro) dipeptide | 154.07 | C₇H₁₀N₂O₂ | 95 | PE, AT |
| 16  | Cyclo (Leu–Leu) dipeptide | 226.17 | C₁₂H₂₂N₂O₂ | 63 | PE |
| 17  | Cyclo (Phe–Leu) dipeptide | 260.15 | C₁₅H₂₀N₂O₂ | 68 | PE |
| 18  | Cyclo (Phe–Pro) dipeptide | 244.12 | C₁₄H₁₆N₂O₂ | 98 | PE |
| 19  | Cyclo (Pro–Pro) dipeptide | 194.11 | C₁₀H₁₄N₂O₂ | 94 | PE, EA |
| 20  | Cyclo (Ala–Val) dipeptide | 170.11 | C₆H₁₀N₂O₂ | 64 | PE |
| 21  | Benzenepropanoic acid, methyl ester | 164.08 | C₁₀H₁₄O₂ | 95 | PE |
| 22  | Ethyl citrate | 276.12 | C₁₂H₂₂O₇ | 83 | PE, AT |
| 23  | Hexadecanonic acid, ethyl ester | 284.26 | C₁₆H₃₂O₂ | 93 | AT |
| 24  | Hexadecanonic acid, methyl ester | 270.26 | C₁₅H₃₀O₂ | 99 | PE, EA, AT |
| 25  | Octadecanoic acid, methyl ester | 298.29 | C₁₈H₃₈O₂ | 98 | EA, AT |
| 26  | 2-Piperidinone | 99.07 | C₅H₉NO | 91 | PE, EA, AT |
| 27  | 2-Pyrrolidinone | 85.05 | C₄H₇NO | 90 | EA |

a Q for match quality. b PE for petroleum ether extract, EA for ethyl acetate extract, AT for acetone extract. GC/MS was used for this analysis.
The secondary metabolites produced by W1 strain were characterized through LC-ESI-MS in a positive full scan mode. Eight pairs of peaks were observed (Table 4), of which six pairs of peaks grouped into two clusters with a fold difference of 14 Da, indicating the presence of two groups of homolog molecules. The first group includes four pairs of peaks corresponding to the protonate adducts and sodium adducts, at $m/z$ 1031.54 $[M + H]^+$ and 1053.53 $[M + Na]^+$, 1045.55 $[M + H]^+$ and 1067.55 $[M + Na]^+$, 1059.56 $[M + H]^+$ and 1081.57 $[M + Na]^+$, and 1073.60 $[M + H]^+$ and 1095.57 $[M + Na]^+$. Therefore, the molecular masses of these four molecules were calculated as 1030.53, 1044.54, 1058.55, and 1072.59, respectively. First group consist of four peaks which are consistent with the molecular mass of Bacillomycin D C14. (A) LC-ESI-MS full scan spectrum of the bacillomycin D C14. (B) ESI-MS/MS spectrum analysis of the precursor ion $[M + H]^+$ at $m/z$ 1031.54. (C) The theoretical b-ion and y-ion fragments dissociated from ring-opening reactions between Glu and Pro. (D) Structure of bacillomycin D C14.

Table 4 Assignments of precursor ions detected by LC-ESI-MS for secondary metabolites of Bacillus velezensis W1

| No. | $t_R$ (min) | Observed peaks ($m/z$) | Compound name | Exact mass |
|-----|-------------|------------------------|---------------|-----------|
|     |             | $[M + H]^+$ | $[M + Na]^+$ | $[M + K]^+$ |                       |
| 1   | 31.462      | 1031.54      | 1053.53      | —          | Bacillomycin D C14    | 1030.53 |
| 2   | 33.013      | —           | 425.23       | 441.21     | Macrolactin A         | 402.24  |
| 3   | 33.298      | 1045.55      | 1067.55      | —          | Bacillomycin D C15    | 1044.54 |
| 4   | 35.167      | 1059.56      | 1081.57      | —          | 7-O-Malonyl-macrolactin A | 488.25  |
| 5   | 35.357      | 1073.60      | 1095.67      | —          | Bacillomycin D C16    | 1058.55 |
| 6   | 37.288      | 1022.71      | 1044.66      | —          | Bacillomycin D C17    | 1072.59 |
| 7   | 57.175      | 1036.69      | 1058.67      | —          | Surfactin C14         | 1021.70 |
| 8   | 59.170      | —           | —            | —          | Surfactin C15         | 1035.68 |
bacillomycin D C14, bacillomycin D C15, bacillomycin D C16, and bacillomycin D C17. Its chemical structures consist of a heptapeptide molecule connected to a β-amino acid fatty chain of 14–17 carbon atoms.\(^\text{16}\)

The protonated molecules [M + H]\(^+\) at \(m/z\) 1031.54, 1045.55, 1059.56, and 1073.60 were selected as precursor ions for further ESI-MS/MS analyses. Fig. 3A showed the ESI-MS spectrum with peaks at \(m/z\) 1031.54 [M + H]\(^+\), 1053.53 [M + Na]\(^+\), and its isotope ion peaks. Fig. 3B showed the ESI-MS/MS spectrum of the most abundant precursor ion at \(m/z\) 1031.54, showing fragment ions, where the ions at \(m/z\) 1031.54, 1013.52, 995.49, and 977.48, respectively, corresponded to the formations of [M + H]\(^+\) [M + H – H\(_2\)O]\(^+\), [M + H – 2H\(_2\)O]\(^+\), and [M + H – 3H\(_2\)O]\(^+\). The remaining fragment ions were identified as y-ion series and b-ion series, which originated from the initial opening of the peptide bond between glutamate and proline in the ring (Fig. 3C). As shown in Fig. 3A, the y-ion series protonated ions at \(m/z\) 902.49 (y\(_7\)), 815.46 (y\(_6\)), 489.20 (y\(_4\)), 375.15 (y\(_3\)), 657.34 (b\(_5\)), 525.54 (b\(_4\)), and 336.27 (b\(_3\)) were observed in ESI-MS/MS spectrum (Fig. 3A). The other fragment protonated ions at \(m/z\) 754.39 and 736.37 were corresponded to [M + H/C\(_4\)H\(_2\)O]\(^+\), and [M + H/C\(_6\)H\(_2\)O]\(^+\), respectively. According to these regular CID fragments, the sequence could be deduced as Glu–Ser–Thr–BAA–Asn–Tyr–Asn–Pro, where BAA shorts for β-amino fatty acid. Therefore, the structure could be identified as bacillomycin D C14 (Fig. 3D). Similarly, the other homolog molecules of the first set were identified as bacillomycin D C15, bacillomycin D C16, and bacillomycin D C17 (Table 4). The other spectra were shown in Fig. S4–S6.\(^\text{17}\)

The sodium adducts [M + Na]\(^+\) at \(m/z\) 1044.66 and 1058.67 were taken as precursor ions for ESI-MS/MS study. Fig. 4A showed ESI-MS spectrum with peaks at \(m/z\) 1036.68 [M + H]\(^+\), 1058.67 [M + Na]\(^+\). The ESI-MS/MS spectrum of the precursor ion at \(m/z\) 1058.67 was shown in Fig. 4A with the appearance of fragment ions. The ions at \(m/z\) 1058.67, 392.27, and 320.24 corresponded to ion formations [M + Na]\(^+\), [Leu–Leu–Asp + Na + CO]\(^+\), and [Leu–Leu–Val + Na – CO]\(^+\), respectively. The remaining fragment ions were assigned as y-ion and b-ion series deriving from the initial opening of the lactone ring (Fig. 4A3). As shown in Fig. 4A2, the y-ion series of the sodium adducts included fragment ions at \(m/z\) 818.49 (y\(_7\)), 707.42 (y\(_6\) + H\(_2\)O), 671.46 (y\(_6\) – H\(_2\)O), 594.35 (y\(_5\) + H\(_2\)O), 481.27 (y\(_4\) + H\(_2\)O), 463.25 (y\(_4\)), and 364.26 (y\(_3\)). The b-ion series of the sodium adducts included fragment ions at \(m/z\) 917.67 (b\(_7\) – CO), 832.50 (b\(_6\)), 717.49 (b\(_5\)), and 618.40 (b\(_4\)). According to these typical CID fragments, the sequence could be deduced as BHA–Glu–Leu–Leu–Val–Asp–Leu–Leu, where BHA represents the shortness of β-hydroxyl fatty acid, and its structure can be identified as

---

**Fig. 4**  LC-ESI-MS/MS tandem mass spectra of surfactin C15 (A1) and surfactin C14 (B1). ESI-MS/MS spectra analysis of the precursor ion [M + H]\(^+\) at \(m/z\) 1058.67 (A2) and 1044.66 (B2). The theoretical b-ion and y-ion fragments of surfactin C15 (A3) and surfactin C14 (B3). (A3). Structures of surfactin C15 (A4) and surfactin C14 (B4).

© 2021 The Author(s). Published by the Royal Society of Chemistry
surfactin C15 (Fig. 4A4). Similarly, by comparing their mass spectra, another one was identified as surfactin C14. For example, their molecular mass differed by 14 Da (Fig. 4B1), they have the same y-ion series ions, and the b-ion series are different by 14 Da (Fig. 4B2 and B3).

The pair of peaks at \( m/z \) 425.23 and \( m/z \) 441.21 (Fig. 5A1) corresponded to the sodium adduct \([M + Na]^+\) and potassium adduct \([M + K]^+\), indicating a molecular mass of 402.24 that was in agreement with the molecular mass of macrolactin A (Fig. 5A2). The \( m/z \) 425.23 was used as the precursor ion for further ESI-MS/MS analyses (Fig. 5A3). The results showed the appearance of protonated fragment ions at \( m/z \) 403.21, 344.23, 333.24, 287.20, 261.08, 237.19, and 217.16. The ion at \( m/z \) 403.21 corresponded to protonated molecule \([M + H]^+\). The ion at \( m/z \) 344.23 corresponded to \([M1 + H]^+\) where \( M1 \) (Fig. 5A2) is derived from the macrolactin A opening from the lactone ring and losing one formic acid residue (COO: 43.99 Da). The ion at \( m/z \) 333.24 corresponded to \([M2 + H]^+\) where \( M2 \) is derived from \( M1 \), losing a methine (CH: 13.01 Da). The ion at \( m/z \) 287.20 corresponded to \([M3 + H]^+\) where \( M3 \) is derived from \( M2 \), losing a vinylene (CHCH: 26.02 Da). The ion at \( m/z \) 261.08 corresponded to \([M4 + H]^+\) where \( M4 \) is derived from \( M3 \), losing vinyl alcohol (CH\(_2\)CHOH: 44.03 Da). The ions at \( m/z \) 237.19 and 217.16, respectively, corresponded to \([M5 + H]^+\) and \([M5 + H + COO]^-\) where \( M5 \) is derived from \( M4 \) losing a vinylene (CHCH: 26.02 Da).

The pair of peaks at \( m/z \) 511.23 \([M + Na]^+\) and \( m/z \) 527.21 \([M + K]^+\) (Fig. 5B1) indicated a molecular mass of 488.25 that was in agreement with the molecular mass of 7-O-malonyl-macrolactin A (Fig. 5B2). The \( m/z \) 511.23 was used as the precursor ion for further ES-MS/MS analyses (Fig. 5B3). The results showed the appearance of product ions at \( m/z \) 423.19, 408.24, and 364.17, respectively, corresponded to \([M1 + Na]^+\), \([M2 + Na]^+\) and \([M3 + Na]^+\). As shown in Fig. 5B2, 7-O-malonyl-macrolactin A lost a malonyl group (COCH\(_2\)COOH: 87.01 Da) to yield \( M1 \), and lost a hydrogen malonate ion (COOCH\(_2\)COOH: 103.00 Da) to produce \( M2 \), and further lost one formic acid residue (COO: 43.99 Da) to get \( M3 \).

**Virtual screening for acaricidal active secondary metabolites**

The previous\(^9\) and present research resulted that a total of 43 (Table S2†) compounds were identified from the strain W1 through genome mining, CG-MS analysis, LC-MS/MS analysis, MALDI TOF-MS analysis, and bioassay-guided fractionation. These 43 compounds were used to screen for acaricidal activity through BindingDB Web service, in which 16 compounds (Table 5) were selected as candidate compounds for acaricidal activity using the criteria of maximum similarity \( \geq 50\% \), mainly including four categories of structures, i.e., cyclodipeptides, bacillomycin D, macrolactin A, and surfactins.

Cyclodipeptides, also known as 2,5-diketopiperazines, are the smallest cyclic peptides, and are known to exhibit various biological and pharmaceutical activities, such as antibacterial, antimicrobial, anticancer, cytotoxic, insecticidal, antioxidant, antiviral, and nematicidal.\(^{19,20}\) Our previous research also reported that cyclodipeptides have acaricidal activity.\(^9\) Bacillomycins D, a kind of lipopeptides belonging to the iturin family, is well known for its antifungal activity, also showed many biological activities such as antimicrobial, antioxidation, anti-tumor, and plant growth-promoting activities.\(^{14,21}\) Macrolactin A is a 24-membered polyene macrolide antibiotic with various biological activities including antibacterial, antifungal, anti-angiogenic, anti-metastatic, and anti-inflammatory.\(^{22–24}\) Surfactin, a cyclic lipopeptide biosurfactant, exhibits a wide range of biocontrol activities, such as

![Fig. 5](image-url)
phytophagous mite compounds. Research results open new insights into the four types of environment, food and pharmaceuticals, but there are scarce lites in the form of cyclodipeptides. Previous studies have obtained information on some metabo- secondary metabolites displayed excellent acaricidal activity. Among them, 16 compounds had a highly chemical structure similarity to the known acaricides, indicating that they have potential acaricidal activity. These 16 putative active compounds belong to 4 chemical structures, designated as cyclodipeptides, bacillomycins, macroactins, and surfactins, in which cyclodipeptides have been proven to have acaricidal and insecticidal ability 9, 19, 20, while other compounds have little research report on acaricidal activity. Further, more the emerging research is being conducted to investigate the acaricidal activity and mechanism of action of 16 compounds into a successful interdisciplinary approach.

**Author contributions**

X. Y. L., Y. X., Y. Q. H., and Y. H. W., conceived and designed the study and experiments; X. Y. L., Y. X., and S. M., performed the experiments; analyzed the data; X. Y. L., Y. X., and S. M., wrote the manuscript; and all authors contributed to the final draft of the manuscript.

**Conflicts of interest**

There are no conflicts to declare.

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (31660536).

**References**

1. O. N. Reva, D. Z. H. Swanevelder, L. A. Mwita, A. D. Mwakilili, D. Muzondiwa, M. Joubert, W. Y. Chan, S. Lutz, C. H. Ahrens, L. V. Avdeeva, M. A. Kharkhota, D. Tibuhwa, S. Lyantagaye, J. Vater, R. Borriss and J. Meijer, *Front. Microbiol.*, 2019, **10**, 2610.

2. H. Cawoy, W. Bettiol, P. Fickers and M. Ongena, in *Pesticides in the modern world-pesticides use and management*, InTech, Rijeka, 2011, pp. 273–302.

3. M. F. Rabbee, M. S. Ali, J. Choi, B. S. Hwang, S. C. Jeong and K. H. Back, *Molecules*, 2019, **24**(6), 1046.

4. K. Blin, S. Shaw, K. Steinke, R. Villebro, N. Ziemert, S. Y. Lee, M. H. Medema and T. Weber, *Nucleic Acids Res.*, 2019, **47**, W81–W87.

5. R. Sigrist, B. S. Paulo, C. F. F. Angolini and L. G. De Oliveira, *J. Visualized Exp.*, 2020, (157), e60825.

6. D. Filimonov, D. Druzhilovskiy, A. Lagunin, T. Gloriozova, A. Rudik, A. Dmitriev, P. Pogodin and V. Poroikov, *Biomedical Chemistry: Research and Methods*, 2018, **1**, e00004.

7. M. K. Gilson, T. Liu, M. Baitaluk, G. Nicola, L. Hwang and J. Chong, *Nucleic Acids Res.*, 2015, **44**, D1045–D1053.

8. X.-Y. Li, S. Munir, W.-Y. Cui, P.-J. He, J. Yang, P.-F. He, Y.-X. Wu, Y.-H. Wang and Y.-Q. He, *Appl. Ecol. Environ. Res.*, 2019, **17**, 2689–2699.

9. X.-Y. Li, Y.-H. Wang, J. Yang, W.-Y. Cui, P.-J. He, S. Munir, P.-F. He, Y.-X. Wu and Y.-Q. He, *J. Agric. Food Chem.*, 2018, **66**, 10163–10168.

10. P. Durai, Y.-J. Ko, C.-H. Pan and K. Park, *BMC Bioinf.*, 2020, **21**, 309.
11 X.-H. Chen, J. Vater, J. Piel, P. Franke, R. Scholz, K. Schneider, A. Koumoutsi, G. Hitzeroth, N. Grammel and A. W. Strittmatter, *J. Bacteriol.*, 2006, **188**, 4024–4036.
12 L. Chen, J. Heng, S. Qin and K. Bian, *PLoS One*, 2018, **13**, e0198560.
13 H. Pan, X. Tian, M. Shao, Y. Xie, H. Huang, J. Hu and J. Ju, *Appl. Microbiol. Biotechnol.*, 2019, **103**, 4153–4165.
14 F. Lin, Y. Xue, Z. Huang, M. Jiang, F. Lu, X. Bie, S. Miao and Z. Lu, *Appl. Microbiol. Biotechnol.*, 2019, **103**, 7663–7674.
15 N. Thasana, B. Prapagdee, N. Rangkadilok, R. Sallabhan, S. L. Aye, S. Ruchirawat and S. Loprasert, *FEBS Lett.*, 2010, **584**, 3209–3214.
16 Q. Gong, C. Zhang, F. Lu, H. Zhao, X. Bie and Z. Lu, *Food Control*, 2014, **36**, 8–14.
17 Y. Meng, H.-Z. Gang, S.-Z. Yang, R.-Q. Ye and B.-Z. Mu, *Anal. Sci.*, 2018, **34**, 541–545.
18 J. Yuan, B. Li, N. Zhang, R. Waseem, Q. Shen and Q. Huang, *J. Agric. Food Chem.*, 2012, **60**, 2976–2981.
19 A. K. Mishra, J. Choi, S.-J. Choi and K.-H. Baek, *Molecules*, 2017, **22**, 1796.
20 X. Wang, Y. Li, X. Zhang, D. Lai and L. Zhou, *Molecules*, 2017, **22**, 2026.
21 T. Wu, M. Chen, L. Zhou, F. Lu, X. Bie and Z. Lu, *Appl. Microbiol. Biotechnol.*, 2020, 1–12.
22 F. Kaspar, P. Neubauer and M. Gimpel, *J. Nat. Prod.*, 2019, **82**, 2038–2053.
23 J. P. Marino, M. S. McClure, D. P. Holub, J. V. Comasseto and F. C. Tucci, *J. Am. Chem. Soc.*, 2002, **124**, 1664–1668.
24 X. L. Lu, Q. Z. Xu, X. Y. Liu, X. Cao, K. Y. Ni and B. H. Jiao, *Chemistry & biodiversity*, 2008, **5**, 1669–1674.
25 G. Seydlová and J. Svobodová, *Open Med.*, 2008, **3**, 123–133.
26 A. W. Zanotto, A. Valério, C. J. de Andrade and G. M. Pastore, *Appl. Microbiol. Biotechnol.*, 2019, **103**, 8647–8656.
27 L. Chen, X.-y. Chong, Y.-y. Zhang, Y.-y. Lv and Y.-s. Hu, *Curr. Microbiol.*, 2020, **77**, 71–78.